Cordyceps militaris Capsules: RCT for COPD Lung Function
TLDR
A 2026 protocol proposes a 160‑patient, double‑blind, placebo‑controlled trial to see if Cordyceps militaris capsules can slow the decline in post‑bronchodilator FEV1 over 24 weeks in people with mild‑to‑moderate COPD. The plan defines the endpoints and safety monitoring, but no data exist yet.
The Big Question
Can a mushroom‑derived capsule keep the lungs from getting weaker in early COPD?
The study, led by Siqi Lin and colleagues, will enroll 160 adults (40–85 yrs) with stable, mild‑to‑moderate COPD. After a one‑week run‑in, participants receive either Cordyceps militaris capsules or a matching placebo for 24 weeks, followed by another 24 weeks of observation. Randomization is 1:1 and the trial is double‑blind.
What the Protocol Says (ROSE)
R – Research
This is the first formal study examining Cordyceps militaris capsules in COPD. The design follows standard RCT rules: blinding, a control group, predefined outcomes. A sample of 160 gives the trial enough power to detect a clinically relevant change in post‑bronchodilator FEV1.
O – Outcome
Primary: change in post‑bronchodilator FEV1 from baseline to 24 weeks.
Secondary: pre‑ and post‑bronchodilator FEV1, FVC, FEV1/FVC, MMEF, FEF75, FEF50, exacerbation frequency, time to first exacerbation, and patient‑reported measures (CAT, CASA‑Q, EQ‑5D‑5L, mMRC). All are measured at baseline, 12 weeks, 24 weeks, and during follow‑up.
S – Strength
The randomized, double‑blind, placebo‑controlled set‑up gives moderate methodological rigor (Evidence Grade B). The focus on mild‑to‑moderate COPD means results may not apply to severe disease. The cohort is modest, and because this is a protocol, no results are available yet.
E – Explain
The trial is designed to test whether Cordyceps militaris capsules can preserve lung function in early COPD. At this stage, it only outlines how the hypothesis will be examined; it does not yet show any benefit or safety beyond what the endpoints will capture.
Primary and Secondary Outcomes
- Primary: change in post‑bronchodilator FEV1 (L) after 24 weeks.
- Secondary:
- Pre‑ and post‑bronchodilator FEV1, FVC, FEV1/FVC ratio.
- MMEF, FEF75, FEF50.
- Exacerbation frequency and time to first exacerbation.
- CAT, CASA‑Q, EQ‑5D‑5L, mMRC scores.
All are assessed at baseline, 12 weeks, 24 weeks, and during the 24‑week follow‑up.
What It Does NOT Prove
- Efficacy: The protocol does not provide evidence that the capsules improve or preserve lung function; it only shows how the trial will test this.
- Safety Beyond Measured Outcomes: Adverse events will be recorded, but the protocol does not guarantee safety or predict rare side effects.
- Long‑Term Benefits: The total 48‑week duration limits conclusions about long‑term disease progression or mortality.
- Applicability to All COPD Stages: Results will apply only to mild‑to‑moderate COPD; they cannot be extrapolated to severe or very early disease.
Evidence at a Glance
| Evidence Grade | Risk Level | Confidence |
|---|---|---|
| B | Low | Moderate confidence that the study design is sound, but no results yet. |
Takeaway
The Cordyceps militaris capsules trial is a well‑structured attempt to evaluate a traditional medicine approach in COPD. It is carefully planned but, as a protocol, provides no proof of benefit or harm yet. Outcomes will be limited to the defined patient group and endpoints.
Frequently Asked Questions
What is Cordyceps militaris?
Cordyceps militaris is a fungal species used in Chinese medicine and cultivated as a supplement. Its respiratory benefits remain under investigation.
What is the purpose of this trial?
To determine whether daily capsules of Cordyceps militaris can slow the decline of post‑bronchodilator FEV1 and improve other lung‑function and quality‑of‑life measures in mild‑to‑moderate COPD.
How many patients will be involved?
The study plans to enroll 160 adults aged 40–85 with stable COPD, randomized equally to capsule or placebo.
Which outcomes will be measured?
Primary: change in post‑bronchodilator FEV1. Secondary: additional lung‑function indices, exacerbation frequency, and patient‑reported questionnaires (CAT, CASA‑Q, EQ‑5D‑5L, mMRC).
Will the study show efficacy?
No results are available yet. Efficacy will be judged only after the trial is completed and data are analyzed.
Internal‑Link Suggestions
- Cordyceps militaris effects on immunity → Cordyceps and Immune Modulation
- COPD progression and lung function decline → Understanding COPD Progression
- Understanding FEV1 and its clinical relevance → What FEV1 Tells Us About Lung Health
- Traditional Chinese medicine in respiratory disease → TCM Approaches to Respiratory Health
- Design of randomized controlled trials in pulmonology → How Pulmonary RCTs Are Conducted
Sources
- Evaluating Cordyceps militaris capsules on post-bronchodilator FEV1 decline in patients with COPD: a study protocol for double‑blind, randomized, placebo‑controlled trial. https://doi.org/10.3389/fphar.2026.1775068
“`
Educational Disclaimer
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
